Ballentine Partners’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.9K | Sell |
16,840
-2,179
| -11% | -$2.7K | ﹤0.01% | 983 |
|
|
2025
Q1 | $22.4K | Sell |
19,019
-10,133
| -35% | -$12K | ﹤0.01% | 904 |
|
|
2024
Q4 | $53.3K | Buy |
29,152
+3,845
| +15% | +$7.04K | ﹤0.01% | 875 |
|
|
2024
Q3 | $43K | Buy |
+25,307
| New | +$43K | ﹤0.01% | 835 |
|
|
2024
Q1 | – | Sell |
-11,248
| Closed | -$110K | – | 753 |
|
|
2023
Q4 | $110K | Sell |
11,248
-696
| -6% | -$6.83K | ﹤0.01% | 659 |
|
|
2023
Q3 | $99.7K | Sell |
11,944
-12
| -0.1% | -$100 | ﹤0.01% | 577 |
|
|
2023
Q2 | $159K | Sell |
11,956
-5,632
| -32% | -$74.9K | ﹤0.01% | 563 |
|
|
2023
Q1 | $204K | Sell |
17,588
-2,542
| -13% | -$29.4K | 0.01% | 518 |
|
|
2022
Q4 | $165K | Buy |
20,130
+8,214
| +69% | +$67.2K | ﹤0.01% | 475 |
|
|
2022
Q3 | $69K | Buy |
11,916
+1,737
| +17% | +$10.1K | ﹤0.01% | 467 |
|
|
2022
Q2 | $45K | Buy |
+10,179
| New | +$45K | ﹤0.01% | 434 |
|
|
2021
Q4 | – | Sell |
-8,270
| Closed | -$211K | – | 482 |
|
|
2021
Q3 | $211K | Buy |
8,270
+136
| +2% | +$3.47K | 0.01% | 390 |
|
|
2021
Q2 | $284K | Sell |
8,134
-479
| -6% | -$16.7K | 0.01% | 330 |
|
|
2021
Q1 | $287K | Sell |
8,613
-56
| -0.6% | -$1.87K | 0.01% | 311 |
|
|
2020
Q4 | $225K | Buy |
+8,669
| New | +$225K | 0.01% | 340 |
|
|
2020
Q2 | – | Sell |
-12,078
| Closed | -$37K | – | 384 |
|
|
2020
Q1 | $37K | Sell |
12,078
-967
| -7% | -$2.96K | ﹤0.01% | 339 |
|
|
2019
Q4 | $67K | Buy |
+13,045
| New | +$67K | ﹤0.01% | 406 |
|